



## **ABIVAX presented this week new pre-clinical data on ABX464 during scientific conference on “HIV Drug Therapy” in Glasgow, Scotland**

October 27, 2016

**ABIVAX presented this week new pre-clinical data on ABX464 during scientific conference on “HIV Drug Therapy” in Glasgow, Scotland**

**Results indicate that reservoir cells may be key target for ABX464's primary metabolite**

**Paris, October 27<sup>th</sup>, 2016** – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, announced today that the Company presented new pre-clinical data on ABX464, ABIVAX's first-in-class drug candidate for the treatment of patients with HIV/AIDS, during this week's HIV Drug Therapy 2016 meeting in Glasgow, Scotland. ABIVAX's presentation is entitled, “Differential effects of ABX464 and its primary metabolite ABX464-NGlc on HIV replication in human PBMC's and macrophages: implications for treatment strategies to eliminate the reservoirs”.